Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
Crossref DOI link: https://doi.org/10.1186/s13075-017-1466-y
Published Online: 2017-12-15
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Curtis, Jeffrey R.
Winthrop, Kevin
O’Brien, Cathy
Ndlovu, Matladi N.
de Longueville, Marc
Haraoui, Boulos
Funding for this research was provided by:
UCB (Not applicable)
